Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosures
3. FDA approved drugs for melanoma up to Feb 2011
4. FDA approved drugs for melanoma in 2011
5. Targeting T cells with ipilimumab
6. Targeted immunotherapy - CTLA4 blockade
7. Ipilimumab in stage IV melanoma
8. Ipilimumab plus DTIC in stage IV melanoma
9. Randomized phase II trial: 3 doses of Ipilimumab
10. Ipilimumab and immune related adverse events
11. Vemurafenib (V600 mutant BRAF inhibitor)
12. Targeting BRAF melanoma with vemurafenib
13. Vemurafenib effects on stage IV BRAF melanoma
14. Unanticipated adverse effect of BRAF inhibitors
15. MEK inhibitors block skin lesions in rats
16. Dabrafenib+trametinib in stage IV melanoma
17. “Standard” approach to melanoma treatment
18. Thank you for your attention

Topics Covered

• Overview of new treatments approved for advanced melanoma in the past few years
• Pegylated interferon alfa-2b
• Ipilimumab
• Mechanism of action
• Impact on progression-free and overall survival
• Overview of immune-related adverse events
• Vemurafenib
• Mechanism of action
• Impact on progression-free and overall survival
• Induction of secondary squamous cell carcinomas
• Possible role for combined RAF/MEK inhibition
• A "standard" approach to treatment of stage IV melanoma

Links

Categories:

• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Dermatology
• Oncology

Talk Citation

Publication History

• Published on May 19, 2013

Financial Disclosures

• Dr. Vernon K. Sondak has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.